Durability and mechanistic performance of aztreonam/avibactam versus aztreonam plus ceftazidime/avibactam against Stenotrophomonas maltophilia complex

阿兹屈南 药代动力学 嗜麦芽窄食单胞菌 头孢他啶 药效学 最小抑制浓度 药理学 医学 微生物学 抗生素 人口 抗菌剂 最低杀菌浓度 丝氨酸 化学 体内 有效剂量(辐射) 细菌 生物
作者
Ashlan J. Kunz Coyne,Rachel Gray,Pavani Gonnabathula,Elizabeth S. May,Paul Puccio,Christine Wu
出处
期刊:Journal of Antimicrobial Chemotherapy [Oxford University Press]
卷期号:81 (6) 被引量:2
标识
DOI:10.1093/jac/dkag177
摘要

BACKGROUND: Stenotrophomonas maltophilia complex infections are difficult to treat because of intrinsic resistance mediated by the L1 metallo-β-lactamase and L2 serine β-lactamase. Although aztreonam/avibactam is clinically available, aztreonam combined with ceftazidime/avibactam remains an alternative, but comparative pharmacodynamic data under clinically relevant exposures are limited. We compared aztreonam/avibactam and aztreonam + ceftazidime/avibactam under prolonged human-simulated dosing. METHODS: Three clinical S. maltophilia complex isolates (17061, 17639 and 16852) were studied in 96-h hollow fibre infection models. Human-simulated aztreonam/avibactam and aztreonam + ceftazidime/avibactam regimens were administered as 3-h extended or continuous infusions at total daily aztreonam doses of 6 g or 8 g. blaL1 and blaL2 expression was quantified by RT-qPCR, and population pharmacokinetic modelling with Monte Carlo simulation (n = 1000) verified target exposures. RESULTS: At 6 g/day of aztreonam, neither aztreonam/avibactam nor aztreonam + ceftazidime/avibactam achieved sustained bactericidal activity; extended infusions failed to produce killing, and continuous infusion produced only transient bactericidal effects followed by regrowth. In contrast, continuous-infusion aztreonam/avibactam at 8 g/day produced rapid and durable bactericidal activity across all isolates through 96 h with stable minimum inhibitory concentrations (MICs), whereas aztreonam + ceftazidime/avibactam at the same dose achieved early killing followed by regrowth. Transcriptionally, aztreonam/avibactam limited or uncoupled blaL1 and blaL2 induction even at intensified dosing, while aztreonam + ceftazidime/avibactam more consistently promoted blaL1 up-regulation and greater β-lactamase variability. CONCLUSIONS: Under human-simulated conditions, only continuous-infusion aztreonam/avibactam with intensified aztreonam exposure (8 g/day) achieved durable bactericidal activity against S. maltophilia complex, whereas adding ceftazidime did not improve pharmacodynamic outcomes and was associated with greater β-lactamase induction.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
1秒前
1秒前
1秒前
缥缈月光发布了新的文献求助10
2秒前
小羽完成签到,获得积分10
2秒前
WW完成签到,获得积分10
3秒前
3秒前
大气的fgyyhjj完成签到,获得积分10
4秒前
4秒前
Hello的应助被怕孤单的德天采纳,获得10
4秒前
谦让钥匙完成签到,获得积分10
4秒前
ami发布了新的文献求助10
4秒前
翟思宇发布了新的文献求助10
4秒前
5秒前
5秒前
何浏亮发布了新的文献求助10
5秒前
6秒前
DW的应助被小马采纳,获得10
8秒前
闲云野鹤完成签到,获得积分10
8秒前
彬彬完成签到,获得积分10
9秒前
谦让钥匙发布了新的文献求助10
9秒前
吗喽发布了新的文献求助10
9秒前
沉睡千年的蛆完成签到,获得积分10
10秒前
典雅秋白完成签到,获得积分10
10秒前
zyy发布了新的文献求助30
10秒前
温骐华完成签到 ,获得积分10
11秒前
缥缈月光完成签到,获得积分10
12秒前
共享精神的应助被敖烈采纳,获得10
12秒前
moose完成签到 ,获得积分10
12秒前
欢喜的乐安完成签到,获得积分10
12秒前
HaoruMeng发布了新的文献求助20
12秒前
13秒前
14秒前
寂寞的飞珍完成签到,获得积分10
14秒前
玛卡巴卡发布了新的文献求助10
15秒前
16秒前
乐乐的应助被Yanzhang0000采纳,获得10
16秒前
吗喽完成签到,获得积分10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181940
求助须知:如何正确求助?哪些是违规求助? 9571697
关于积分的说明 21819181
捐赠科研通 7778330
什么是DOI,文献DOI怎么找? 3433556
关于科研通互助平台的介绍 2557767
邀请新用户注册赠送积分活动 2479621